NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jun 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
SUPRENZA (phentermine hydrochloride) by Camallergy is obesity, amphetamine (d- and d l l-amphetamine). Approved for hypertension. First approved in 2011.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUPRENZA is an orally disintegrating tablet formulation of phentermine hydrochloride, a sympathomimetic amine anorectic approved in 2011. It is indicated for obesity management and works as an amphetamine derivative that suppresses appetite, though additional CNS and metabolic mechanisms may be involved. The orally disintegrating formulation provides an alternative delivery route for patients with difficulty swallowing conventional tablets.
LOE Approaching2.4 years to LOE
Product is approaching loss of exclusivity with formulation patent expiring March 2029, signaling likely contraction of commercial team and shift toward lifecycle management strategies.
Mechanism of Action
obesity, amphetamine (d- and d l l-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system…
Indications (1)
Why This Matters for Your Career
Worked on SUPRENZA at Camallergy? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.